Clinical Trials Logo

Clinical Trial Summary

Multicentre, prospective, observational, non-interventional, open- ended trial, collecting data from male and female patients aged ≥ 18 years, with a diagnosis of opioid addiction according to ICD-10 (F11.2), treated with therapeutic doses of levomethadone according to the routine medical practice.


Clinical Trial Description

Multicentre, prospective, observational, non-interventional, open- ended trial, collecting data from male and female patients aged ≥ 18 years, with a diagnosis of opioid addiction according to ICD-10 (F11.2), treated with therapeutic doses of levomethadone according to the routine medical practice. The study is divided in two different consecutive parts: - Part 1 [from Informed Consent form (ICF) to last data collected at V4]: patients enrolled are receiving levomethadone maintenance treatment according to clinical practice. - Part 2 (after V4 up to FU): patients are in opioid maintenance treatment with any drug (including levomethadone) according to clinical practice. The maximum duration on-study for a patient will be 405 days [from ICF signature (-30 days from V1) to FU (=360 + 15)]. This study is an open-ended trial. This means that for the enrolment and for the study, no maximum duration has been established. The study, which is a voluntary Post Authorization Safety Study (PASS), will be carried out on approximately 10 centers in Italy. The objectives are to provide further data on the safety profile after long term use and effectiveness of levomethadone, administered according Summary of Product Characteristics (SmPC) and in a real word clinical setting, in opioid-addicted patients undergoing maintenance treatment. Safety will be assessed throughout all the study and safety data will be described and analysed based on Adverse Drug Reactions and corrected QT (QTc) prolongation at 12-lead electrocardiogram (ECG), where available. The effectiveness outcomes are the evaluation of levomethadone maintenance treatment according to investigator's judgment at V4(180 days), based on different questionnaires and assessment. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03685162
Study type Observational
Source L.Molteni & C. dei F.lli Alitti-Soc. di Esercizio S.p.A.
Contact
Status Completed
Phase
Start date February 27, 2018
Completion date February 16, 2023

See also
  Status Clinical Trial Phase
Completed NCT04336293 - sTMS for Substance Use-disordered Veterans N/A
Completed NCT01188421 - Medications Development for Drug Abuse Disorders Phase 1/Phase 2
Completed NCT00499746 - The Discriminative Effects of Tramadol in Humans Phase 1/Phase 2
Not yet recruiting NCT05611749 - Duloxetine Impact on Postoperative Pain Control and Outcomes Phase 2
Recruiting NCT04325659 - An Innovative Intervention for OUD Treatment Phase 2/Phase 3
Recruiting NCT04239235 - Integrating Support Persons Into Recovery N/A
Not yet recruiting NCT03394911 - Healthy Adult Male Facial Skin Surface Lipid Pheromone p.o. to Treat Opioid Addiction Phase 3
Not yet recruiting NCT02282072 - PINS Stimulator System for Deep Brain Stimulation of the Nucleus Accumbens to Treat Severe Opioid Addiction Phase 0
Not yet recruiting NCT01008072 - Ultra-rapid Opiate Detoxification Using Deep Sedation and Prior Oral Buprenorphine Preparation. N/A
Completed NCT02696096 - Neuroimaging Predictors of Relapse During Treatment for Opiate Dependence Phase 3
Recruiting NCT05299515 - Peer Activate: Trial of Peer-Delivered Behavioral Activation for Methadone Adherence N/A
Recruiting NCT04309565 - Transitions Clinic Network: Post Incarceration Addiction Treatment, Healthcare, and Social Support N/A
Completed NCT01873989 - Testosterone Replacement for Male Opioid Agonist Maintained Patients Phase 1/Phase 2
Completed NCT01590251 - Yoga for Pain and Opioid Dependence Phase 1/Phase 2
Active, not recruiting NCT02866266 - ER/LA Opioid Surveillance for Emergency Department Visits and Hospitalizations for Overdose and Poisoning N/A
Enrolling by invitation NCT02871232 - Surveillance Monitoring of Opioid Abuse in Poison and Drug Treatment Centers N/A